Association of Leptin With Obesity and Insulin Resistance

Ratan Kumar 1, Kheraj Mal 2, Muhammad Khalid Razaq 3, Hansoor Magzi 4, Muhammad Khizar Memon 5, Sidra Memon 6, Maham Noor Afroz 7, Humza F. Siddiqui 8, Amber Rizwan 9

1. Cardiology, Khairpur Medical College, Khairpur, PAK 2. Cardiology, National Institute of Cardiovascular Diseases, Karachi, PAK 3. Cardiology, Sheikh Zayed Medical College, Rahim Yar Khan, PAK 4. Internal Medicine, Taluka Hospital Kandhkot, Kandhkot, PAK 5. Internal Medicine, Liaquat University of Medical & Health Sciences, Jamshoro, PAK 6. Internal Medicine, Jinnah Sindh Medical University, Karachi, PAK 7. Medicine and Surgery, Jinnah Sindh Medical University, Karachi, PAK 8. Oncology, Jinnah Post Graduate Medical Center, Karachi, PAK 9. Family Medicine, Jinnah Post Graduate Medical Center, Karachi, PAK

Corresponding author: Amber Rizwan, amber_aljazeera109@hotmail.com

Abstract

Introduction

Leptin, a hormone released by the body to regulate energy balance by inhibiting hunger, decreases fat storage in adipocytes. Leptin is thought to play some role in obesity and insulin resistance. In this study, our aim is to see the association of leptin with obesity and insulin resistance.

Methods

This case-control study was conducted in a tertiary care hospital in Pakistan from January 2020 to April 2020. Ninety-two participants with BMI greater than 25 kg/m², with no known comorbidities were enrolled in the study after informed consent. Ninety-two participants, who came to the outpatient department without a history of chronic disease, with BMI less than 25 kg/m² were enrolled as a control group. Data were collected via self-structured questionnaires. Their blood was drawn and sent to the laboratory for cholesterol levels, insulin resistance and leptin levels.

Results

Serum leptin levels (51.24 ± 18.12 vs. 9.10 ± 2.99: p-value, < 0.0001), serum cholesterol levels (198.2 ± 32.1 vs. 151.2 ± 21.2, p-value < 0.0001) and insulin resistance (7.9 ± 2.1 vs. 6.3 ± 1.9, p-value < 0.0001) were higher in obese patients.

Conclusion

As per the results of this study, obesity was associated with increase serum leptin levels and insulin resistance. Further multi-centric studies are required to prove the possible relationship, which might help devise plans to manage obesity.

Categories: Endocrinology/Diabetes/Metabolism, Internal Medicine
Keywords: leptin, obesity, insulin resistance, diabetes

Introduction

Leptin is a hormone released by adipose tissue and small intestine cells to regulate energy balance in proportion to triglycerides via certain neural pathways mainly hypothalamus to inhibit hunger which in turn decreases fat storage in adipocytes [1–4]. Because of its mode of action, leptin is thought to play some role in the development of obesity and insulin resistance [2,3,5].

Obesity is a complex phenomenon in which there is deposition of excess amount of fat. It increases the risk of cardiovascular diseases (CVDs), stroke, osteoarthritis, diabetes, and reproductive functions [6]. Globally, the prevalence of obesity has steadily increased during the past 30 years [7]. Izquierdo AG et al., in his review article, suggested that obese people have elevated serum levels of leptin as explained by leptin resistance in such individuals [8]. This resistance leads to failure of hunger suppression and increased food intake, which ultimately leads to obesity [9]. Obese individuals are also more likely to develop insulin resistance and have high cholesterol levels, which can lead to development of numerous chronic illnesses [5]. Obesity, leptin resistance and insulin resistance are interrelated. Studies have suggested that hyperinsulinemina can be a potential cause of leptin resistance and hence obesity, eventually leading to metabolic syndrome in such individuals [10].

Although global research has been done on the association between leptin, obesity and insulin resistance,
however, as per our knowledge, there is no local data available regarding this subject in the Pakistani population.

**Materials And Methods**

This case-control study was conducted in a tertiary care hospital in Pakistan. Data were collected from the attendant of patients visiting the outpatient department of the medicine ward from January 2020 to April 2020. Ninety-two participants with BMI greater than 25 kg/m$^2$, without any known comorbidities such as hypertension, diabetes or previous history of cardiovascular events were enrolled in the study after informed consent. Ninety-two participants, who came to the outpatient department without a history of chronic disease, with BMI less than 25 kg/m$^2$ were enrolled as a control group.

After the inclusion of participants in the study, their demographics such as age, BMI, gender, and smoking history were noted in self-structured questionnaires. Their blood was drawn and sent to the laboratory for cholesterol levels, insulin resistance and leptin levels. The serum levels of leptin were measured using a radioimmunoassay (RIA) (normal range: 2.5-21.8 ng/mL) [11].

Statistical analysis was done using SPSS, v. 23.0 (IBM Corporation, Armonk, NY). Continuous variables including age, insulin resistance, body mass index, cholesterol levels and leptin levels were analyzed via descriptive statistics and were presented as means and SDs while categorical variables such as smoking history were presented as percentages and frequencies. T-test and Chi-square were applied as appropriate. p-value of less than 0.05 meant that the difference between the groups is significant and the null hypothesis is void.

**Results**

Leptin was significantly higher in patients with obesity (51.24 ± 18.12 vs. 9.10 ± 2.99: p-value < 0.0001). Cholesterol (198.2 ± 32.1 vs. 151.2 ± 21.2, p-value < 0.0001) and insulin resistance (7.9 ± 2.1 vs. 6.3 ± 1.9, p-value < 0.0001) were also significantly higher in patients with obesity (Table 1).

| Characteristics (mean ± SD) | BMI more than 25 kg/m$^2$ | BMI less than 25 kg/m$^2$ | p-value |
|----------------------------|---------------------------|---------------------------|---------|
| Age (years)                | 49 ± 12                   | 47 ± 11                   | Not significant |
| Gender                     |                           |                           |         |
| Male                       | 35 (38.0%)                | 47 (51.0%)                | Not Significant |
| Female                     | 57 (62.0%)                | 45 (49.0%)                |         |
| Body Mass Index (kg/m$^2$) | 28.2 ± 3.1                | 21.1 ± 1.5                | < 0.0001 |
| Insulin Resistance (mU/L)  | 7.9 ± 2.1                 | 6.3 ± 1.9                 | < 0.0001 |
| Cholesterol Levels (mg/L)  | 198.2 ± 32.1              | 151.2 ± 21.2              | < 0.0001 |
| Smoking Status (%)         | 32 (34.7%)                | 26 (28.2%)                |         |
| Total Leptin (ng/mL)       | 51.24 ± 18.12             | 9.10 ± 2.99               | < 0.0001 |

**TABLE 1: Comparison between obese and non-obese patients.**

Leptin levels were above normal level in 52.2% obese patients compared to 13.1% in non-obese patients. The odds ratio was 7.7 (3.49-15.11, 95% CI) (Table 2).
Leptin (ng/mL)

| Normal Level (below 21.8 ng/mL) | Obese Patients (n = 92) | Non-Obese patients (n = 92) | 95% CI | OR |
|---------------------------------|-------------------------|-----------------------------|--------|----|
| Normal Level (below 21.8 ng/mL) | 44 (47.8%)              | 80 (86.9%)                  | 3.49-15.11 | 7.27 |
| Increased Level (above 21.8 ng/mL) | 48 (52.2%)              | 12 (13.1%)                 |        |    |

TABLE 2: Leptin levels in obese vs. non-obese patients.
CI, confidence interval; OR, odds ratio.

Discussion

Obesity and insulin resistance are the primary components of metabolic syndrome and these are the main modifiable risk factors for cardiovascular disease. Positive correlation between obesity and insulin resistance has been well documented. However, they also share another common link in the form of hyperleptinemia. Studies have observed that obesity causes high levels of leptin, which acts as a pro-inflammatory cytokine and amplifies the process of insulin resistance [12].

This study demonstrated significantly higher levels of leptin in obese patients (51.24 ± 18.12) than non-obese patients (9.10 ± 2.99) with p-value < 0.0001. Moreover, greater than 50% of the obese patients had leptin levels above 21.8 ng/ml while only 15.1% non-obese showed these levels. Minocci et al. also reported similar findings that increased BMI was associated with increased leptin levels. These levels were directly proportional to subcutaneous fat and were inversely proportional to abdominal fat index and/or waist-hip ratio [13]. This is the plausible explanation that might explain why leptin levels were higher in females rather than in males. As females acquire fat deposition in subcutaneous depot and males acquire more visceral fat [14]. This sexual dimorphism was also found in another study conducted by Couillard and his colleagues. They demonstrated that high levels of leptin are associated with adipose cell hypertrophy, which is seen more in females as compared to adipose tissue hyperplasia seen commonly in males [15].

As leptin reduces appetite and body weight, the paradoxical coexistence of obesity and hyperleptinemia suggests the pathology of “leptin resistance” [16]. Leptin resistance can be due to defect in intracellular mechanism or due to impairment in transport through blood-brain barrier. Several pathways related to the development of leptin resistance have been studied in animal models such as the fat mass and obesity-related gene, oestradiol (E2) and peroxisome proliferator-activated receptor γ, phosphodiesterase-3B (PDE3B)-cAMP- and Akt-pathways of leptin signalling in the hypothalamus [17,18]. These findings open the door to understanding the pathophysiology of leptin resistance in humans. On the other hand, congenital leptin deficiency is associated with hyperphagia and early-onset obesity. This goes along with the basic physiology of leptin and its effects on hypothalamus as an anti-obesity hormone [19,20].

Insulin resistance (IR) is defined as the inability of the known quantity of insulin hormone to impart its effects on the body tissue as it does in the normal population [21]. In this study, we found out IR was 7.9 ± 2.1 in obese patients which is much higher than 6.3 ± 1.9 in non-obese patients. The pathophysiology behind obesity-induced IR and diabetes mellitus type 2 (DM2) is thought to be due to systemic inflammation. Prolinflammatory cytokines such as Interleukin 1 beta (IL-1β) have been implicated to induce IR through the activation NLR family pyrin domain containing 3 (NLRP3) inflammasome [22].

Leptin also has a role in inflammation. High levels of leptin are positively associated with systemic markers of inflammation such as serum amyloid A (SAA), C-reactive protein (CRP) and osteopontin as well with markers of systemic oxidation such as thiobarbituric acid reactive substances (TBARS) [23]. This observation was further proved by another study where Uslu et al enrolled 85 DM2 patients and found an increased level of leptin (a proinflammatory adipocytokine) and decreased level of adiponectin (an anti-inflammatory cytokine). The author also suggested the application of leptin and adiponectin ratio as a CVD risk factor in DM2 patients [24].

To the best of knowledge, this is the first local study that studies the correlation between body mass index and leptin level. There are certain limitations for the study as well. First, since it is a case-control study, no definite association can be established. Also, since the study was conducted in single-center, the sample diversity was reduced.

Leptin is an important marker and may play a role in obesity, cardiovascular disease, inflammation, insulin resistance and diabetes mellitus type 2. It is important that leptin levels are periodically monitored in high-risk patients and appropriate management to reduce leptin levels is done.

Conclusions
In this study, high levels of leptin were associated with increased BMI and insulin resistance. Leptin is the hallmark of obesity and is a major appetite suppressant, although no effective obesity therapy based on this hormone has been developed till date. Role of leptin in obesity and insulin resistance and its effectiveness in the management of obesity is under many studies. Physicians should be encouraged to include leptin levels in the management of obesity and other metabolic syndromes.

Additional Information

Disclosures

**Human subjects:** Consent was obtained by all participants in this study. Khairpur Medical College issued approval KMC/IRB-Off/18-82. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Myers MG Jr, Münzberg H, Leinninger GM, et al.: The geometry of leptin action in the brain: more complicated than a simple ARC. Cell Metab. 2009, 9:117-123. 10.1016/j.cmet.2008.12.001
2. Schwartz MW, Woods SC, Porte D Jr, et al.: Central nervous system control of food intake. Nature. 2000, 404:661-671. 10.1038/35075534
3. Rosenbaum M, Leibel RL: The role of leptin in human physiology. N Engl J Med. 1999, 341:915-915. 10.1056/NEJM199901163411211
4. Ahima RS, Saper CB, Flier JS, et al.: Leptin regulation of neuroendocrine systems. Front Neuroendocrinol. 2000, 21:263-307. 10.1006/fneu.2000.0197
5. Osege I, Okpara H, Azirige E: Relationship between serum leptin and insulin resistance among obese Nigerian women. Ann Afr Med. 2016, 15:14-19. 10.4103/1596-3519.158724
6. Lainé NR, Cost D: Obesity, neuroinflammation, and reproductive function. Endocrinology. 2019, 160:2719-2736. 10.1210/en.2019-00457
7. NCD Risk Factor Collaboration (NCD-RisC): Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants [published correction appears in. Lancet. 2016, 14:1377-1376. 10.1016/S0140-6736(16)30505-X
8. Izquierdo AG, Crujeiras AB, Casanueva FF, et al.: Leptin, obesity, and leptin resistance: where are we 25 years later?. Nutrients. 2019, 8:2704. 10.5590/mui1112704
9. Liu J, Yang X, Yu S, et al.: The leptin resistance. Adv Exp Med Biol. 2018, 1090:145-153. 10.1007/978-981-15-1286-1_8
10. Lustig RH, Sen S, Soherman E, et al.: Obesity, leptin resistance, and the effects of insulin reduction. Int J Obes. 2004, 28:1344-1348. 10.1038/sj.ijo.0802753
11. Takeda T, Sato Y, Matsumoto H: Serum leptin concentration positively correlates with body weight and total fat mass in postmenopausal Japanese women with osteoarthritis of the knee. Arthritis. 2011, 2011:S80632. 10.1155/2011/S80632
12. López-Jaramillo P, Gómez-Arbeláez D, López-López J, et al.: The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Hormone Mol Biol Clin Invest. 2014, 18:37-45. 10.1515/hmbci-2013-0053
13. Minocci A, Savia G, Lucantoni R, et al.: Leptin plasma concentrations are dependent on body fat distribution in obese patients. Int J Obes. 2000, 24:1139-1144. 10.1038/sj.ijo.0801385
14. Palmer BF, Clegg DJ: The sexual dimorphism of obesity. Mol Cell Endocrinol. 2015, 402:113-119. 10.1016/j.mce.2014.11.029
15. Cosuillard C, Maurice P, Imbeault P, et al.: Hyperleptinemia is more closely associated with adipose cell hypertrophy than with adipose tissue hyperplasia. Int J Obes. 2000, 24:782-788. 10.1038/sj.ijo.0801227
16. Myers MG Jr, Leibel RL, Sleyel RJ, et al.: Obesity and leptin resistance: distinguishing cause from effect. Trends Endocrinol Metab. 2010, 21:643-651. 10.1016/j.tem.2010.08.002
17. Banks WA: Role of the blood-brain barrier in the evolution of feeding and cognition. Ann NY Acad Sci. 2012, 1264:13-19. 10.1111/j.1749-6632.2012.06568.x
18. Farr OM, Gavrieli A, Mantzoros CS: Leptin applications in 2015: what have we learned about leptin and obesity?. Curr Opin Endocrinol Diab Obes. 2015, 22:553-559. 10.1097/MED.0000000000000184
19. Fatima W, Shahid A, Imran M, et al.: Leptin deficiency and leptin gene mutations in obese children from Pakistan. Int J Pediatr Obes. 2011, 6:419-427. 10.3109/17477166.2011.608431
20. Ekmen N, Helvaci A, Gunaldi M, et al.: Leptin as an important link between obesity and cardiovascular risk factors in men with acute myocardial infarction. Indian Heart J. 2016, 68:132-137. 10.1016/j.ihj.2015.07.032
21. Lebovitz HE: Insulin resistance: definition and consequences. Exp Clin Endocrinol Diab. 2001, 109:S135-S148. 10.1055/s-2001-18576
22. Esser N, Legrand-Poels S, Piette J, et al.: Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diab Res Clin Pract. 2014, 105:141-150. 10.1016/j.diabres.2014.04.006
23. Frühbeck G, Catalán V, Rodríguez A, et al.: Involvement of the leptin-adiponectin axis in inflammation and oxidative stress in the metabolic syndrome. Scientific Rep. 2017, 7:6619. 10.1038/s41598-017-06997-0
24. Uulu S, Keçapçı N, Kara M, et al.: Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus. Exp Ther Med. 2012, 4:115-120. 10.3892/etm.2012.557